Clinical Trial Update: Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating safety of immunotherapy induction with tremelimumab and durvalumab before chemoradiotherapy and/or resection in Stage III non-small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Stage III NSCLC | Phase 1 | Status: TERMINATED